ArticlemAbs2016

The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax®.

Bishu Ganguly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.